SecBot SecBot

RADX

Radiopharm Theranostics Ltd
Nasdaq· Pharmaceutical Preparations· Inc. C3· CIK 0001949257 Biotech & Drug Discovery
$0.9169 −0.08 (−7.94%)
Oct 27 4:00 PM ET · prev $0.9960
Market cap
$14.6M
Nano cap
Median target
🔒 Subscribers only
1 year
−82.6%
from $5.28 · Oct 27
30 days
−39.7%
from $1.52
52-week range
$0.9169–10.63
at the low
Avg volume 20D
48.6K
Oct 13 spike 143.1K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
29
analyzed by SecBot
SecBot read MIXED 23 reports · 90 days
Balance 4 bearish · 4 bullish · 3 mixed · 12 neutral oldest → newest, height = score
Avg score ·High conf. 16/23
Strongest BULLISH Radiopharm Theranostics announced successful completion of an End-of-Phase 2 meeting with the FDA for…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • TrendDOWNTREND

    45% below its 50-day average. New closing low $0.9169 on Oct 27.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
PNC FINANCIAL SERVICES GROUP, INC.ADD20,000$83.8K
UBS Group AGTRIM1,507$6.3K
RHUMBLINE ADVISERSADD195$817.00
HSBC HOLDINGS PLCTRIM61,372$264.5K
UBS Group AGNEAR_EXIT3,000$12.9K
RHUMBLINE ADVISERSDOUBLED121$519.00
PNC FINANCIAL SERVICES GROUP, INC.DOUBLED16,000$88.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Jun 4, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$3.23-$3.23–-$3.23—$1.1M
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 5, 2026
Trading halt
Halt Resumed: RADX — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-05T13:42:49.000Z | Resumed 2026-10-05T13:47:49.000Z
Oct 5, 2026
Trading halt
Trading Halt: RADX — LUDP (Volatility Trading Pause)
Radiopharm Theranostics ADS | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 9, 2026
FDA
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
Positive safety and favourable biodistribution seen in all subjects dosed
Aug 26, 2026
FDA
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company’s joint venture with MD Anderson Cancer…
Aug 20, 2026
FDA
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Oct 5, 2026Volatility PauseResumed
Jul 24, 2026Volatility PauseResumed
Jul 24, 2026Volatility PauseResumed
Jul 24, 2026Volatility PauseResumed
Jul 21, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 26, 2026 SEC
Radiopharm Theranostics announced it received $8 million from Rockford Capital under a funding facility secured…
6-K — Impact 4/10
Oct 20, 2026 SEC
Radiopharm Theranostics filed a 6-K reporting that four directors (Bruce Goodwin, Ian Turner, Paul Hopper, Riccardo…
6-K — Impact 3/10
Oct 5, 2026 Trading halt
Halt Resumed: RADX — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-05T13:42:49.000Z | Resumed 2026-10-05T13:47:49.000Z
Aug 20, 2026 Press
Radiopharm Theranostics announced a positive DSMC recommendation to advance its radiotherapeutic RAD202 to the next…
Impact 4/10
Aug 17, 2026 Press
Radiopharm Theranostics announced an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the Phase 3…
Impact 7/10
Jun 30, 2026 Inst.
PNC FINANCIAL SERVICES GROUP, — ADD
20,000 shares ($83.8K)
Jun 30, 2026 Inst.
UBS Group AG — TRIM
1,507 shares ($6.3K)

SecBot reports

29 filings · 4 press releases · 5 bullish · 9 bearish · 3 mixed · 12 neutral
All RADX filing & press-release reports (33)